Terms: = Prostate cancer AND FOXO4, P98177, 4303, ENSG00000184481, MLLT7, AFX1 AND Treatment
5 results:
1. Regulatory effects of antitumor agent matrine on FOXO and PI3K-AKT pathway in castration-resistant prostate cancer cells.
Li Q; Huang H; He Z; Sun Y; Tang Y; Shang X; Wang C
Sci China Life Sci; 2018 May; 61(5):550-558. PubMed ID: 29119376
[TBL] [Abstract] [Full Text] [Related]
2. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote prostate Tumorigenesis and Cell Invasion.
Yang Y; Blee AM; Wang D; An J; Pan Y; Yan Y; Ma T; He Y; Dugdale J; Hou X; Zhang J; Weroha SJ; Zhu WG; Wang YA; DePinho RA; Xu W; Huang H
Cancer Res; 2017 Dec; 77(23):6524-6537. PubMed ID: 28986382
[TBL] [Abstract] [Full Text] [Related]
3. Norcantharidin induces mitochondrial-dependent apoptosis through Mcl-1 inhibition in human prostate cancer cells.
Lin CL; Chen CM; Lin CL; Cheng CW; Lee CH; Hsieh YH
Biochim Biophys Acta Mol Cell Res; 2017 Oct; 1864(10):1867-1876. PubMed ID: 28760656
[TBL] [Abstract] [Full Text] [Related]
4. Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice.
Shukla S; Bhaskaran N; Maclennan GT; Gupta S
Prostate; 2013 Oct; 73(14):1507-17. PubMed ID: 23765843
[TBL] [Abstract] [Full Text] [Related]
5. Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores.
Berger AP; Gozzi C; Steiner H; Frauscher F; Varkarakis J; Rogatsch H; Bartsch G; Horninger W
J Urol; 2004 Apr; 171(4):1478-80; discussion 1480-1. PubMed ID: 15017202
[TBL] [Abstract] [Full Text] [Related]
